Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer

Alessia Cimadamore, Silvia Gasparrini, Matteo Santoni, Liang Cheng, Antonio Lopez-Beltran, Nicola Battelli, Francesco Massari, Francesca Giunchi, Michelangelo Fiorentino, Marina Scarpelli, Rodolfo Montironi

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Introduction: Over the last decade, the improvement in molecular techniques and the acquisition of genomic information has transformed and increased the quality of patient care and our knowledge of diseases. Areas covered: Protein expression levels in immunohistochemistry and molecular biomarkers are reported for their ability to predict recurrence, progression, development of metastases, or patient survival. In particular, for renal cell carcinoma, we take into consideration the biomarkers applicable to immunohistochemistry and with molecular and genetic analyses. In urothelial carcinoma, there is great interest in the possibility of distinguishing the basal vs. luminal subtypes and to acquire deeper insight into the tumor biology through examining exosomes in urine and biomarkers in the serum. In prostate cancer, single gene expression and multiple gene expression classifiers are reviewed as a tool to distinguish indolent vs. aggressive disease. Expert commentary: The genomic information along with the application of ancillary techniques allow the definition of a neoplasia not only by its morphology but also by its biological signature. This continuous increase in knowledge will result in a better comprehension of oncogenesis, development of targeted therapies and optimizing decision-making processes related to patient care.

Original languageEnglish (US)
Pages (from-to)645-655
Number of pages11
JournalExpert Review of Molecular Diagnostics
Volume18
Issue number7
DOIs
StatePublished - Jul 3 2018

Fingerprint

Kidney Neoplasms
Urinary Bladder Neoplasms
Prostatic Neoplasms
Biomarkers
Patient Care
Immunohistochemistry
Exosomes
Gene Expression
Neoplasms
Aptitude
Quality of Health Care
Renal Cell Carcinoma
Molecular Biology
Decision Making
Carcinogenesis
Urine
Neoplasm Metastasis
Carcinoma
Recurrence
Survival

Keywords

  • Biomarkers
  • genomic assays
  • prostate cancer
  • renal cell carcinoma
  • risk assessment
  • urothelial cancer

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer. / Cimadamore, Alessia; Gasparrini, Silvia; Santoni, Matteo; Cheng, Liang; Lopez-Beltran, Antonio; Battelli, Nicola; Massari, Francesco; Giunchi, Francesca; Fiorentino, Michelangelo; Scarpelli, Marina; Montironi, Rodolfo.

In: Expert Review of Molecular Diagnostics, Vol. 18, No. 7, 03.07.2018, p. 645-655.

Research output: Contribution to journalReview article

Cimadamore, A, Gasparrini, S, Santoni, M, Cheng, L, Lopez-Beltran, A, Battelli, N, Massari, F, Giunchi, F, Fiorentino, M, Scarpelli, M & Montironi, R 2018, 'Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer', Expert Review of Molecular Diagnostics, vol. 18, no. 7, pp. 645-655. https://doi.org/10.1080/14737159.2018.1490179
Cimadamore, Alessia ; Gasparrini, Silvia ; Santoni, Matteo ; Cheng, Liang ; Lopez-Beltran, Antonio ; Battelli, Nicola ; Massari, Francesco ; Giunchi, Francesca ; Fiorentino, Michelangelo ; Scarpelli, Marina ; Montironi, Rodolfo. / Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer. In: Expert Review of Molecular Diagnostics. 2018 ; Vol. 18, No. 7. pp. 645-655.
@article{4e21da4b26314e8db9999362212307a4,
title = "Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer",
abstract = "Introduction: Over the last decade, the improvement in molecular techniques and the acquisition of genomic information has transformed and increased the quality of patient care and our knowledge of diseases. Areas covered: Protein expression levels in immunohistochemistry and molecular biomarkers are reported for their ability to predict recurrence, progression, development of metastases, or patient survival. In particular, for renal cell carcinoma, we take into consideration the biomarkers applicable to immunohistochemistry and with molecular and genetic analyses. In urothelial carcinoma, there is great interest in the possibility of distinguishing the basal vs. luminal subtypes and to acquire deeper insight into the tumor biology through examining exosomes in urine and biomarkers in the serum. In prostate cancer, single gene expression and multiple gene expression classifiers are reviewed as a tool to distinguish indolent vs. aggressive disease. Expert commentary: The genomic information along with the application of ancillary techniques allow the definition of a neoplasia not only by its morphology but also by its biological signature. This continuous increase in knowledge will result in a better comprehension of oncogenesis, development of targeted therapies and optimizing decision-making processes related to patient care.",
keywords = "Biomarkers, genomic assays, prostate cancer, renal cell carcinoma, risk assessment, urothelial cancer",
author = "Alessia Cimadamore and Silvia Gasparrini and Matteo Santoni and Liang Cheng and Antonio Lopez-Beltran and Nicola Battelli and Francesco Massari and Francesca Giunchi and Michelangelo Fiorentino and Marina Scarpelli and Rodolfo Montironi",
year = "2018",
month = "7",
day = "3",
doi = "10.1080/14737159.2018.1490179",
language = "English (US)",
volume = "18",
pages = "645--655",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "7",

}

TY - JOUR

T1 - Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer

AU - Cimadamore, Alessia

AU - Gasparrini, Silvia

AU - Santoni, Matteo

AU - Cheng, Liang

AU - Lopez-Beltran, Antonio

AU - Battelli, Nicola

AU - Massari, Francesco

AU - Giunchi, Francesca

AU - Fiorentino, Michelangelo

AU - Scarpelli, Marina

AU - Montironi, Rodolfo

PY - 2018/7/3

Y1 - 2018/7/3

N2 - Introduction: Over the last decade, the improvement in molecular techniques and the acquisition of genomic information has transformed and increased the quality of patient care and our knowledge of diseases. Areas covered: Protein expression levels in immunohistochemistry and molecular biomarkers are reported for their ability to predict recurrence, progression, development of metastases, or patient survival. In particular, for renal cell carcinoma, we take into consideration the biomarkers applicable to immunohistochemistry and with molecular and genetic analyses. In urothelial carcinoma, there is great interest in the possibility of distinguishing the basal vs. luminal subtypes and to acquire deeper insight into the tumor biology through examining exosomes in urine and biomarkers in the serum. In prostate cancer, single gene expression and multiple gene expression classifiers are reviewed as a tool to distinguish indolent vs. aggressive disease. Expert commentary: The genomic information along with the application of ancillary techniques allow the definition of a neoplasia not only by its morphology but also by its biological signature. This continuous increase in knowledge will result in a better comprehension of oncogenesis, development of targeted therapies and optimizing decision-making processes related to patient care.

AB - Introduction: Over the last decade, the improvement in molecular techniques and the acquisition of genomic information has transformed and increased the quality of patient care and our knowledge of diseases. Areas covered: Protein expression levels in immunohistochemistry and molecular biomarkers are reported for their ability to predict recurrence, progression, development of metastases, or patient survival. In particular, for renal cell carcinoma, we take into consideration the biomarkers applicable to immunohistochemistry and with molecular and genetic analyses. In urothelial carcinoma, there is great interest in the possibility of distinguishing the basal vs. luminal subtypes and to acquire deeper insight into the tumor biology through examining exosomes in urine and biomarkers in the serum. In prostate cancer, single gene expression and multiple gene expression classifiers are reviewed as a tool to distinguish indolent vs. aggressive disease. Expert commentary: The genomic information along with the application of ancillary techniques allow the definition of a neoplasia not only by its morphology but also by its biological signature. This continuous increase in knowledge will result in a better comprehension of oncogenesis, development of targeted therapies and optimizing decision-making processes related to patient care.

KW - Biomarkers

KW - genomic assays

KW - prostate cancer

KW - renal cell carcinoma

KW - risk assessment

KW - urothelial cancer

UR - http://www.scopus.com/inward/record.url?scp=85051128648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051128648&partnerID=8YFLogxK

U2 - 10.1080/14737159.2018.1490179

DO - 10.1080/14737159.2018.1490179

M3 - Review article

C2 - 29912582

AN - SCOPUS:85051128648

VL - 18

SP - 645

EP - 655

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 7

ER -